Could a lower dose of a transplant drug be better for blood cancer patients?

NCT ID NCT05436418

First seen Nov 01, 2025 · Last updated Apr 25, 2026 · Updated 26 times

Summary

This study tests whether a lower dose of the drug cyclophosphamide, given after a stem cell transplant, can better prevent graft-versus-host disease (a common complication where donor cells attack the patient's body) in people with blood cancers like leukemia or lymphoma. About 260 adults who need a transplant from a related donor will receive different doses of the drug along with other medications. Researchers will monitor participants for up to 5 years to find the safest and most effective dose.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEMATOPOIETIC STEM CELL TRANSPLANTATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • City of Hope

    NOT_YET_RECRUITING

    Duarte, California, 91010, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • National Institutes of Health Clinical Center

    RECRUITING

    Bethesda, Maryland, 20892, United States

    Contact Phone: •••-•••-••••

Conditions

Explore the condition pages connected to this study.